What to expect in the Parabilis Medicines, Inc. interview process

Based on publicly available sources, Parabilis Medicines, Inc. (formerly known as FogPharma) is a Cambridge, Massachusetts-based, clinical-stage biopharmaceutical company founded in 2016. Operating with a team of roughly 150 to 200 employees distributed across the United States and China, the company focuses on creating stabilized helical peptide therapeutics—specifically through its proprietary Helicon discovery platform—to target intracellular proteins historically considered undruggable.

The organization is backed by blue-chip life sciences investors, having secured significant financial support with over $831.7 million in total funding across six prior rounds, alongside a major strategic R&D collaboration with Regeneron worth up to $2.3 billion. In mid-2026, the company completed a Nasdaq IPO (trading under the ticker PBLS), marking a major corporate milestone celebrated at the Nasdaq MarketSite in New York and its Cambridge headquarters.

Its scientific pipeline centers on first-in-class programs like FOG-001—a TCF-blocking beta-catenin inhibitor currently in Phase 1/2 clinical trials for colorectal cancer and other solid tumors—as well as functional protein-protein interaction inhibitors, targeted protein degraders, and radiopharmaceuticals. The company integrates artificial intelligence and data science into its drug discovery processes. While overall headcount has grown by approximately 10% to 15% year-over-year, specific internal details regarding day-to-day workplace culture, management styles, return-to-office mandates, or interview evaluation stages are not heavily documented in current public records.